Nasdaq:AKYA

MARLBOROUGH, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be…

MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in two…

MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial…

The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2…

-Company previews an integrated suite of solutions, including the new PhenoCycler™-Fusion System for unbiased spatial discovery, at unprecedented speeds -Innovations include a novel…

MARLBOROUGH, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and PathAI, a global leader in artificial intelligence…

MARLBOROUGH, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that new data generated with its CODEX® and…

MARLBOROUGH, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that the Phenoptics™ mIF solution was used in a…

Investigators at Johns Hopkins University (JHU) used AstroPath to identify and validate biomarkers for accurate prediction of long-term response to immune checkpoint inhibitors in advanced…